--- title: "CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab" type: "News" locale: "en" url: "https://longbridge.com/en/news/276549711.md" description: "CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer. This marks the second indication for the drug in the UK, supported by positive results from the Phase III GEMSTONE-301 trial. CStone is expanding its global presence with commercialization partnerships in over 60 countries and plans further regulatory filings for additional indications. The current analyst rating for CStone's stock (HK:2616) is a Sell with a price target of HK$5.00." datetime: "2026-02-23T00:37:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276549711.md) - [en](https://longbridge.com/en/news/276549711.md) - [zh-HK](https://longbridge.com/zh-HK/news/276549711.md) --- # CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab ### President's Day Sale - 70% Off - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential CStone Pharmaceuticals ( (HK:2616) ) just unveiled an update. CStone Pharmaceuticals announced that the UK Medicines and Healthcare products Regulatory Agency has approved a new indication for its anti-PD-L1 antibody sugemalimab as monotherapy for adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. The decision, supported by the Phase III GEMSTONE-301 trial showing significant progression-free and overall survival benefits, marks the second sugemalimab indication in the UK and strengthens the drug’s position as one of only two PD-(L) 1 antibodies approved for stage III NSCLC in Europe. With commercialization partnerships now covering more than 60 countries and multiple inclusions in national reimbursement systems, CStone is accelerating the global rollout of sugemalimab and enhancing its international oncology presence. The company plans further regulatory filings for additional indications, including gastric cancer and esophageal squamous cell carcinoma, which could broaden its revenue base and reinforce its competitive standing in the global immuno-oncology market. The most recent analyst rating on (HK:2616) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page. **More about CStone Pharmaceuticals** CStone Pharmaceuticals is a China-based biopharmaceutical company focused on the development and commercialization of innovative oncology therapies. Its pipeline centers on immuno-oncology drugs, including the anti-PD-L1 monoclonal antibody sugemalimab, with a growing commercial footprint across Europe, the Middle East, Africa, Latin America and China. **Average Trading Volume:** 8,370,213 **Technical Sentiment Signal:** Strong Buy **Current Market Cap:** HK$8.59B See more insights into 2616 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [02616.HK](https://longbridge.com/en/quote/02616.HK.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) ## Related News & Research - [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md) - [Faron raises EUR 40.1 million in rights issue to advance cancer drug bexmarilimab](https://longbridge.com/en/news/282233028.md) - [Everest’s US$250 million buy signals rising global appetite for China biotech](https://longbridge.com/en/news/282130717.md) - [RaySearch wins first RayCare order in China from P-Cure for Shanghai center](https://longbridge.com/en/news/283100924.md) - [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)